Doug Bakan
PhD

Doug has extensive expertise in all aspects of pharmaceutical drug development and commercialization along with over 35-years of experience in firms ranging in size from entrepreneurial start-ups to established publicly traded companies.  In various roles as an independent consultant or a full-time employee at companies including Kailera Therapeutics, Ventyx Biosciences, Arena Pharmaceuticals (now Pfizer), Medicis Pharmaceuticals (now Valeant Pharmaceuticals), Novalar Pharmaceuticals, Neurocrine Biosciences, Alerion Biomedical, MetaProbe LLC, Corvas International, and Molecular Biosystems, Inc., Doug has been responsible for activities including discovery research, nonclinical and clinical testing, CMC efforts for drug substance and drug product supply (research, clinical, and commercial stage), quality system development and oversight, program management, regulatory dossier preparation and approval, intellectual property creation and prosecution, venture capital financing, technology in-licensing and out-licensing, and technical due diligence.  Most recently, Doug served as Chief Technology Officer at Kailera Therapeutics where he was responsible for all CMC activities for the company’s portfolio of clinical stage GLP-1 assets.  He has been an author on more than 50 scientific publications and abstracts and is an inventor on more than 35 issued or pending patents.  Doug earned his BS in Biomedical Engineering at UC San Diego, his PhD in Biology from UC San Diego, and completed post-doctoral research at the University of Michigan in the laboratories of Drs. Raymond Counsell and Jamey Weichert.